Navigation Links
NxStage(R) Secures $15 Million Revolving Line of Credit

LAWRENCE, Mass., March 11 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM) a leading manufacturer of innovative dialysis products, today announced that it has secured a two-year $15 million revolving line of credit from Silicon Valley Bank (SVB).  

The revolving line of credit is subject to a borrowing base of trade accounts receivable, inventory and field equipment and is secured by substantially all of the Company's assets.  In connection with this Agreement, the Company amended its term loan and security agreement with Asahi to grant Asahi junior liens on certain of the Company's assets.  Borrowings under the Agreement bear interest at a rate per annum equal to two percentage points (2.00%) above the prime rate (initial prime rate of 4%).  

"This new credit facility provides additional financial flexibility at favorable interest rates to finance working capital needs as the business continues to grow and to seize future opportunities, when they arise," stated Robert Brown, Chief Financial Officer of NxStage Medical. "We remain confident in our ability to achieve break-even adjusted EBITDA in the second quarter of 2010 and positive cash flow thereafter."

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements.  Examples of these forward-looking statements include statements as to improvements in Adjusted EBITDA, cash flow and anticipated growth opportunities. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's product, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

    Kristen K. Sheppard, Esq.
    VP, Investor Relations

SOURCE NxStage Medical, Inc.

Back to top



SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)
2. Group of NxStage(R) Home Hemodialysis Patients to Take Caribbean Cruise with the System One(TM)
3. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. NxStage(R) to Report Third Quarter 2009 Financial Results
6. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
7. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
8. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
9. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
10. EnzySurge, Maker of DermaStream(R) Secures US$2.5 Million in Private Capital
11., Inc. Secures $1 Million in Debt Financing
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):